These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8478573)

  • 1. [Cardioprotective effect of cromakalim, a K+ channel opener, on isolated globally ischemic and reperfused rat hearts].
    Taki H; Masuda Y; Yoshizumi M; Kitagawa T; Katoh I
    Nihon Kyobu Geka Gakkai Zasshi; 1993 Mar; 41(3):438-44. PubMed ID: 8478573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
    Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R
    J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cromakalim on ischemic and reperfused immature heart: experiments with isolated neonatal New Zealand white rabbit hearts.
    Shimoe Y; Yoshizumi M; Masuda Y; Kitagawa T; Katoh I
    Tokushima J Exp Med; 1996 Dec; 43(3-4):135-41. PubMed ID: 9100462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide.
    Ferdinandy P; Szilvássy Z; Droy-Lefaix MT; Tarrade T; Koltai M
    Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
    Tosaki A; Szerdahelyi P; Engelman RM; Das DK
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts.
    Tosaki A; Engelman DT; Engelman RM; Das DK
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1115-23. PubMed ID: 8531071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury.
    Lee SH; Yang MK; Lim JH; Seo HW; Yi KY; Yoo SE; Lee BH; Won HS; Lee CS; Choi WS; Shin HS
    Arch Pharm Res; 2008 Apr; 31(4):482-9. PubMed ID: 18449506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides.
    Grover GJ; Newburger J; Sleph PG; Dzwonczyk S; Taylor SC; Ahmed SZ; Atwal KS
    J Pharmacol Exp Ther; 1991 Apr; 257(1):156-62. PubMed ID: 2019983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
    Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ
    J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ischemic preconditioning in immature hearts: mechanism and compatibility with cardioplegia.
    Zhu B; Min S; Long C; Ye T
    Chin Med J (Engl); 2003 Feb; 116(2):253-7. PubMed ID: 12775242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
    Grover GJ; McCullough JR; Henry DE; Conder ML; Sleph PG
    J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pinacidil pretreatment extends ischemia tolerance of neonatal rabbit hearts.
    Feng J; Li H; Rosenkranz ER
    J Surg Res; 2000 May; 90(2):131-7. PubMed ID: 10792953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular Mg++ manipulation prevents the proarrhythmic activity of cromakalim in ischemic/reperfused diabetic hearts.
    Tosaki A; Das DK
    J Pharmacol Exp Ther; 1997 Jul; 282(1):309-17. PubMed ID: 9223569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of ATP-sensitive K+ channels by cromakalim. Effects on cellular K+ loss and cardiac function in ischemic and reperfused mammalian ventricle.
    Venkatesh N; Stuart JS; Lamp ST; Alexander LD; Weiss JN
    Circ Res; 1992 Dec; 71(6):1324-33. PubMed ID: 1423930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim.
    Grover GJ; Sleph PG; Dzwonczyk S; McCullough JR
    J Pharmacol Exp Ther; 1993 Oct; 267(1):102-7. PubMed ID: 8229736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of Na movement on surgical myocardial protection: the role of the Na+-H+ exchange system and Na-channel in the development of ischemia and reperfusion injury.
    Liu KX; Yamamoto F; Yamamoto H; Wang T; Zhu Z; Xu R; Zhang S
    Ann Thorac Cardiovasc Surg; 2007 Oct; 13(5):301-7. PubMed ID: 17954986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. K(ATP)-channel activation: effects on myocardial recovery from ischaemia and role in the cardioprotective response to adenosine A1-receptor stimulation.
    Ford WR; Lopaschuk GD; Schulz R; Clanachan AS
    Br J Pharmacol; 1998 Jun; 124(4):639-46. PubMed ID: 9690854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardioprotective effects of cariporide as an adjunct in different cardioplegic solutions: an experiment with rabbits].
    Zhou RH; Long C; Liu J; Liu B
    Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(33):2320-3. PubMed ID: 18036293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amelioration of ischemia/reperfusion injury in isolated rats hearts by the ATP-sensitive potassium channel opener BMS-180448.
    Monticello TM; Sargent CA; McGill JR; Barton DS; Grover GJ
    Cardiovasc Res; 1996 Jan; 31(1):93-101. PubMed ID: 8849593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
    Grover GJ; D'Alonzo AJ; Garlid KD; Bajgar R; Lodge NJ; Sleph PG; Darbenzio RB; Hess TA; Smith MA; Paucek P; Atwal KS
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.